Compositions are provided which feature mixtures of at least a first and second peptoid. The second peptoid has a terminal aliphatic moiety, while the first peptoid lacks a terminal aliphatic moiety. These compositions have various end uses, including the treatment of various cancers and tumors and the treatment of bacterial, fungal, microbial or parasitic infections.
A method is provided for treating a surface containing a plurality of functional groups. The method includes reacting the plurality of functional groups with a linking group, thereby creating a surface containing a plurality of linking groups; and binding a first peptoid to each of the plurality of linking groups, thereby obtaining a first treated surface.
A method is provided for treating a recipient with a biological product obtained from at least one donor that may be the same as, or different from, the recipient. The method includes identifying a targeted level of gene expression of a first gene in a biological product to be transferred from at least one donor to a recipient; treating the at least one donor to achieve the targeted level of gene expression of the first gene in the biological product; and transferring the biological product from the at least one donor to the recipient.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
A method is provided for treating a subject. The method comprises diagnosing the subject as suffering from a condition arising from the presence in the subject of a causative agent; and administering to the subject a pharmaceutically effective amount of a substance having (a) a hydrophobic, helical region, (b) an N-terminal region that includes at least one proline residue, (c) a first linking moiety that links the hydrophobic helical region to the N-terminal region, said linking moiety being equipped with at least one lysine-like side chain, (d) a binding moiety which binds to the causative agent, and (e) a second linking moiety that links the binding moiety to the N-terminal region.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A contraceptive device is provided which includes a (preferably elastomeric) surface; and a lubricant applied to the surface. The lubricant includes (a) a lubricious medium, and (b) a pharmaceutically effective amount of a peptoid disposed in said lubricious medium. The antimicrobial peptoid may impart protection against some common sexually transmitted diseases, while also imparting spermicidal activity to the lubricious medium and contraceptive device.
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventeur(s)
Barron, Annelise E.
Evans, Andrew K.
Lin, Jennifer S.
Mcclure, Joshua
Shamloo, Mehrdad
Abrégé
A polytherapy of orally available compounds is disclosed that synergistically modulates and induces the expression of the cathelicidin gene (CAMP), which encodes the host defense peptide LL-37. By providing a number of different CAMP-inducing compounds together at the same time, stronger gene induction is achieved than with just one or two compounds, because the mechanism of induction broadens. Induction also may vary in different pas of the body depending on which compounds are used, and at what levels. We show for the first time that the polytherapy can induce cathelicidin expression in the brain, which may help to treat or prevent Alzheimer's Disease Systemic cathelicidin gene induction may help treat numerous other conditions including Type 2 Diabetes/Metabolic Syndrome, or chronic bacterial, viral, or fungal infections associated with increased cancer risk or neurodegeneration. By increasing cellular autophagy and macroautophagy and supporting mitochondrial biogenesis and homeostasis, CAMP gene upregulation may reduce the effects of cellular aging and increase longevity.
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 31/593 - Dérivés du 9,10-séco-cholestane, p.ex. cholécalciférol, vitamine D3
A61K 31/20 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique
A61K 36/889 - Arecaceae, Palmae ou Palmaceae (famille du palmier), p.ex. dattier ou cocotier ou palmier nain
A61K 31/07 - Composés du rétinol, p.ex. vitamine A
7.
SUBSTRATES MODIFIED WITH PEPTOID-LOADED MICROGELS FOR RESISTANCE TO BACTERIAL COLONIZATION
A method is provided for treating a surface of a biomedical device. The method comprises depositing a polyanionic microgel onto the surface of the biomedical device, and loading the deposited polyanionic gel with a peptoid.
A method is provided for treating a subject for a viral infection. The method includes diagnosing the subject as having a viral infection, and administering a pharmaceutically effective amount of a pharmaceutical composition to the subject. The pharmaceutical composition includes a poly-N-substituted glycine compound of a formula AX-Y-Zn—B, wherein A is a terminal N-alkyl substituted glycine residue; n is an integer; B is selected from the group consisting of NH2, one and two N-substituted glycine residues, and wherein said one and two N-substituted glycine residues have N-substituents which are independently selected from natural α-amino acid side chain moieties, isomers and carbon homologs thereof; X, Y and Z are independently selected from the group consisting of N-substituted glycine residues, wherein said N-substituents are independently selected from the group consisting of natural α-amino acid side chain moieties, isomers and carbon homologs thereof, and proline residues. In some embodiments, at least one of A, B, X, Y and Z contains a halogen-bearing moiety.
A method is provided for treating a surface containing a plurality of functional groups. The methopd includes reacting the plurality of functional groups with a linking group, thereby creating a surface containing a plurality of linking groups; and binding a first peptoid to each of the plurality of linking groups, thereby obtaining a first treated surface.
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 38/14 - Peptides contenant des radicaux saccharide; Leurs dérivés
A method is provided for treating a surface containing a plurality of functional groups. The methopd includes reacting the plurality of functional groups with a linking group, thereby creating a surface containing a plurality of linking groups; and binding a first peptoid to each of the plurality of linking groups, thereby obtaining a first treated surface.
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
11.
SURFACTANT PROTEIN C MIMICS DISPLAYING PATHOGEN- OR ALLERGEN-BINDING MOIETIES
A method is provided for treating a subject. The method comprises diagnosing the subject as suffering from a condition arising from the presence in the subject of a causative agent; and administering to the subject a pharmaceutically effective amount of a substance having (a) a hydrophobic, helical region, (b) an N-terminal region that includes at least one proline residue, (c) a first linking moiety that links the hydrophobic helical region to the N-terminal region, said linking moiety being equipped with at least one lysine-like side chain, (d) a binding moiety which binds to the causative agent, and (e) a second linking moiety that links the binding moiety to the N-terminal region.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
A contraceptive device is provided which includes a (preferably elastomeric) surface; and a lubricant applied to the surface. The lubricant includes (a) a lubricious medium, and (b) a pharmaceutically effective amount of a peptoid disposed in said lubricious medium. The antimicrobial peptoid may impart protection against some common sexually transmitted diseases, while also imparting spermacidal activity to the lubricious medium and contraceptive device.
A contraceptive device is provided which includes a (preferably elastomeric) surface; and a lubricant applied to the surface. The lubricant includes (a) a lubricious medium, and (b) a pharmaceutically effective amount of a peptoid disposed in said lubricious medium. The antimicrobial peptoid may impart protection against some common sexually transmitted diseases, while also imparting spermacidal activity to the lubricious medium and contraceptive device.
A method is provided for treating a subject for a viral infection. The method includes diagnosing the subject as having a viral infection, and administering a pharmaceutically effective amount of a pharmaceutical composition to the subject. The pharmaceutical composition includes a poly-N-substituted glycine compound of a formula A-(-X-Y-Z-)n-B, wherein A is a terminal N-alkyl substituted glycine residue; n is an integer; B is selected from the group consisting of NH2, one and two N-substituted glycine residues, and wherein said one and two N-substituted glycine residues have N-substituents which are independently selected from natural a-amino acid side chain moieties, isomers and carbon homologs thereof; X, Y and Z are independently selected from the group consisting of N-substituted glycine residues, wherein said N-substituents are independently selected from the group consisting of natural a-amino acid side chain moieties, isomers and carbon homologs thereof, and proline residues.
A poly-N-substituted glycine compound of a formula A-(X-Y-Z)n-B is provided, wherein A is a terminal N-alkyl substituted glycine residue; n is an integer; B is selected from the group consisting of NH2, one and two N-substituted glycine residues, and wherein said one and two N-substituted glycine residues have N-substituents which are independently selected from natural -amino acid side chain moieties, isomers and carbon homologs thereof; X, Y and Z are independently selected from the group consisting of N-substituted glycine residues, wherein said N-substituents are independently selected from the group consisting of natural -amino acid side chain moieties, isomers and carbon homologs thereof, and proline residues, and wherein at least one of A, B, X, Y and Z contains a halogen-bearing moiety.
A poly-N-substituted glycine compound of a formula A-(X-Y-Z)n-B is provided, wherein A is a terminal N-alkyl substituted glycine residue; n is an integer; B is selected from the group consisting of NH2, one and two N-substituted glycine residues, and wherein said one and two N-substituted glycine residues have N-substituents which are independently selected from natural -amino acid side chain moieties, isomers and carbon homologs thereof; X, Y and Z are independently selected from the group consisting of N-substituted glycine residues, wherein said N-substituents are independently selected from the group consisting of natural -amino acid side chain moieties, isomers and carbon homologs thereof, and proline residues, and wherein at least one of A, B, X, Y and Z contains a halogen-bearing moiety.
A method is provided for treating a recipient with a biological product obtained from at least one donor that may be the same as, or different from, the recipient. The method includes identifying a targeted level of gene expression of a first gene in a biological product to be transferred from at least one donor to a recipient; treating the at least one donor to achieve the targeted level of gene expression of the first gene in the biological product; and transferring the biological product from the at least one donor to the recipient.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
A polytherapy of orally available compounds is disclosed that synergistically modulates and induces the expression of the cathelicidin gene (CAMP), which encodes the host defense peptide LL-37. By providing a number of different CAMP-inducing compounds together at the same time, stronger gene induction is achieved than with just one or two compounds. Induction also may vary in different parts of the body, depending on which compounds are used and at what levels.The polytherapy may induce cathelicidin expression in the brain, which may help to treat or prevent Alzheimers Disease. Systemic cathelicidin gene induction may help treat numerous other conditions including Type 2 Diabetes / Metabolic Syndrome, or chronic bacterial, viral, or fungal infections associated with increased cancer risk or neurodegeneration. By increasing cellular autophagy and macroautophagy and supporting mitochondrial biogenesis and homeostasis, CAMP gene upregulation may reduce the effects of cellular aging and increase longevity.
A61K 31/593 - Dérivés du 9,10-séco-cholestane, p.ex. cholécalciférol, vitamine D3
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
